Search

Indivior PLC

Nyitva

1,242

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

1242

Maximum

1242

Fő mutatók

By Trading Economics

Bevétel

-19M

47M

Értékesítés

-33M

266M

P/E

Szektor átlag

330

38.156

Profit margin

17.669

Munkavállalók

1,030

EBITDA

-30M

76M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+10.23% upside

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

721M

1.5B

Előző nyitás

1242

Előző zárás

1242

Indivior PLC Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2025. júl. 31. 23:56 UTC

Forró részvények

Stocks to Watch: Amazon, Bio-Rad, Coinbase, Mercer

2025. júl. 31. 23:48 UTC

Piaci beszéd

Scentre Can Beat Annual Earnings Guidance -- Market Talk

2025. júl. 31. 23:45 UTC

Piaci beszéd

Nikkei May Decline Amid Caution Over Earnings, Domestic Politics -- Market Talk

2025. júl. 31. 23:37 UTC

Piaci beszéd

Market Talk Roundup: Latest on U.S. Politics

2025. júl. 31. 23:37 UTC

Piaci beszéd

Gold Steady as Traders Eye Tariff-Deal Developments -- Market Talk

2025. júl. 31. 23:12 UTC

Eredményjelentés

OCBC: Evolving Trade, Monetary Policies, Persistent Geopolitical Tensions Expected to Weigh on Growth Prospects >O39.SG

2025. júl. 31. 23:10 UTC

Eredményjelentés

Oversea-Chinese Banking: Declining Interest-Rate Environment Weighed in Net Interest Income >O39.SG

2025. júl. 31. 23:09 UTC

Eredményjelentés

Oversea-Chinese Banking 2Q Net Interest Income S$2.28B Vs. S$2.43B >O39.SG

2025. júl. 31. 23:08 UTC

Eredményjelentés

Oversea-Chinese Banking 2Q Total Income S$3.55B Vs. S$3.63B >O39.SG

2025. júl. 31. 23:08 UTC

Eredményjelentés

Oversea-Chinese Banking 2Q Net S$1.82B Vs. Net S$1.94B >O39.SG

2025. júl. 31. 23:01 UTC

Eredményjelentés

Amazon Posts Higher Sales, Profit -- 3rd Update

2025. júl. 31. 22:08 UTC

Piaci beszéd
Eredményjelentés

Amazon CEO Impressed by Deals Signed for Project Kuiper -- Market Talk

2025. júl. 31. 22:02 UTC

Piaci beszéd
Eredményjelentés

Apple's FY Outlook Shows Sales Growth Won't Last -- Market Talk

2025. júl. 31. 21:57 UTC

Piaci beszéd
Eredményjelentés

Amazon CEO Sees Strong Early Demand for Alexa+ -- Market Talk

2025. júl. 31. 21:50 UTC

Eredményjelentés

Amazon Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

2025. júl. 31. 21:43 UTC

Eredményjelentés

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- 2nd Update

2025. júl. 31. 21:29 UTC

Eredményjelentés

Amazon to Invest More in Chips, Data Centers Amid Generative AI Opportunity, CFO Says

2025. júl. 31. 21:26 UTC

Eredményjelentés

Apple Expects Revenue to Grow in Mid- to High-Single Digits in Current Quarter, CFO Says

2025. júl. 31. 21:26 UTC

Eredményjelentés

MicroStrategy Beats Earnings Estimates. The Stock Rises. -- Barrons.com

2025. júl. 31. 21:22 UTC

Eredményjelentés

Amazon Has Impressive Amount of Agreements for Project Kuiper, CEO Says

2025. júl. 31. 21:19 UTC

Eredményjelentés

Apple Estimates Tariff Impact to Add $1.1B to Costs in Current Quarter, CEO Says

2025. júl. 31. 21:19 UTC

Eredményjelentés

Apple Incurred $800M in Tariff-Related Costs in 2Q, CEO Says

2025. júl. 31. 21:14 UTC

Eredményjelentés

Amazon's AWS is Seeing More Demand Than Supply, CEO Says

2025. júl. 31. 21:12 UTC

Eredményjelentés

Amazon Saw Record Prime Sign-Ups in 3 Weeks Before Prime Day, CEO Says

2025. júl. 31. 21:10 UTC

Eredményjelentés

Amazon Just Getting Started on Automation, Robotics to Boost Efficiency, CEO Says

2025. júl. 31. 21:09 UTC

Eredményjelentés

Amazon Delivered to Prime Members at Record Pace in 2Q, CEO Says

2025. júl. 31. 21:09 UTC

Eredményjelentés

Amazon CEO Sees Diversity of Sellers as Advantage for Inflation-Weary Consumers

2025. júl. 31. 21:08 UTC

Eredményjelentés

Apple iPhone Revenue Performance Driven by Popularity of iPhone 16 Family, CEO Says

2025. júl. 31. 21:08 UTC

Eredményjelentés

Amazon CEO Sees Strong Customer Adoption of Perishables Same-Day Delivery Pilot

2025. júl. 31. 21:05 UTC

Eredményjelentés

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- Update

Indivior PLC Előrejelzés

Célár

By TipRanks

10.23% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 1,364.65 GBX  10.23%

Magas 1,637.581 GBX

Alacsony 967.662 GBX

4 Wall Street elemző 12 hónapos célárain alapulva a(z)Indivior PLC termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

4 ratings

4

Vétel

0

Tartás

0

Eladás

Pénzügyek

$

Rólunk Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
help-icon Live chat